1.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GERN Giù?
Forum
Previsione
Precedente Chiudi:
$1.65
Aprire:
$1.65
Volume 24 ore:
16.13M
Relative Volume:
1.10
Capitalizzazione di mercato:
$1.05B
Reddito:
$29.48M
Utile/perdita netta:
$-201.19M
Rapporto P/E:
-5.1563
EPS:
-0.32
Flusso di cassa netto:
$-216.50M
1 W Prestazione:
-9.34%
1M Prestazione:
-5.17%
6M Prestazione:
-63.89%
1 anno Prestazione:
-50.00%
Geron Corp Stock (GERN) Company Profile
Nome
Geron Corp
Settore
Industria
Telefono
(650) 473-7700
Indirizzo
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Confronta GERN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
GERN
Geron Corp
|
1.65 | 1.05B | 29.48M | -201.19M | -216.50M | -0.32 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Geron Corp Stock (GERN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-27 | Downgrade | B. Riley Securities | Buy → Neutral |
2025-02-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
2024-11-05 | Iniziato | H.C. Wainwright | Buy |
2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
2024-09-09 | Iniziato | Leerink Partners | Outperform |
2024-04-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
2024-04-29 | Iniziato | TD Cowen | Buy |
2024-03-15 | Reiterato | Needham | Buy |
2023-09-12 | Aggiornamento | Goldman | Neutral → Buy |
2023-03-28 | Iniziato | Goldman | Neutral |
2022-10-28 | Iniziato | Wedbush | Outperform |
2022-07-28 | Ripresa | B. Riley Securities | Buy |
2021-11-02 | Iniziato | Robert W. Baird | Outperform |
2021-02-18 | Ripresa | B. Riley Securities | Buy |
2020-08-03 | Iniziato | Stifel | Buy |
2019-11-19 | Ripresa | B. Riley FBR | Buy |
2019-09-03 | Iniziato | H.C. Wainwright | Buy |
2019-08-15 | Iniziato | Cantor Fitzgerald | Overweight |
2019-04-09 | Aggiornamento | Needham | Hold → Buy |
2019-01-31 | Aggiornamento | B. Riley FBR | Neutral → Buy |
2018-10-02 | Downgrade | B. Riley FBR | Buy → Neutral |
2018-07-05 | Iniziato | B. Riley FBR, Inc. | Buy |
2016-09-13 | Reiterato | FBR & Co. | Outperform |
2016-09-13 | Reiterato | FBR Capital | Outperform |
2015-12-07 | Reiterato | Piper Jaffray | Overweight |
2015-04-21 | Iniziato | Oppenheimer | Outperform |
2014-06-12 | Aggiornamento | MLV & Co | Hold → Buy |
2014-03-12 | Downgrade | MLV & Co | Buy → Hold |
2013-12-10 | Reiterato | MLV & Co | Buy |
2013-12-10 | Aggiornamento | Needham | Hold → Buy |
2013-11-08 | Reiterato | MLV & Co | Buy |
2013-10-16 | Iniziato | MLV & Co | Buy |
2012-08-30 | Iniziato | Stifel Nicolaus | Buy |
2012-06-28 | Iniziato | Needham | Hold |
Mostra tutto
Geron Corp Borsa (GERN) Ultime notizie
GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights - PR Newswire
GERN INVESTOR ALERT: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
When Can We Expect A Profit From Geron Corporation (NASDAQ:GERN)? - Yahoo Finance
GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit - Marketscreener.com
GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
GERN Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Geron Corporation (GERN)Contact Kessler Topaz Meltzer & Check, LLP - Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against XPLR, Geron, enCore, and TFI and Encourages Investors to Contact the Firm - TradingView
Deep Track Capital, LP's Strategic Acquisition of Geron Corp Shares - GuruFocus.com
Is Geron Corporation (NASDAQ:GERN) The Top Penny Stock That Will Skyrocket? - Yahoo Finance
Top 10 Penny Stocks That Will Skyrocket - Insider Monkey
GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERN - GlobeNewswire Inc.
Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for InvestorsContact The Gross Law Firm - PR Newswire
GERN INVESTOR NOTICE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Eastern Progress Online
GERN INVESTOR NOTICE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Indo-Asian News Service - IANS India Pvt Ltd
Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - PR Newswire
Geron Corporation Sued for Securities Law ViolationsContact Levi & Korsinsky Before May 12, 2025 to Discuss Your RightsGERN - PR Newswire
Geron reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 19, 2025 at 04:43 pm EDT - Marketscreener.com
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Is Geron (GERN) Among the Most Oversold Penny Stocks to Buy According to Analysts? - Insider Monkey
Geron Corp: How Concerned Should We Be About Rytelo Sales? (NASDAQ:GERN) - Seeking Alpha
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - Markets Insider
10 Most Oversold Penny Stocks to Buy According to Analysts - Insider Monkey
Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
GERN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Geron Corporation Investors - TradingView
GERN INVESTOR ALERT: Geron Corporation Investors with Substantia - GuruFocus.com
GERN INVESTOR ALERT: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Malaysian Reserve
GERN INVESTOR ALERT: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
HC Wainwright Reiterates Neutral Rating for Geron (NASDAQ:GERN) - Defense World
GERN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Investor Brings Securities Class Action Against Geron Corp. (1) - Bloomberg Tax
SBI Securities Co. Ltd. Acquires New Holdings in Geron Co. (NASDAQ:GERN) - Defense World
Geron’s SWOT analysis: biotech stock faces pivotal year for growth By Investing.com - Investing.com South Africa
Geron Corp appoints interim CEO amid leadership shuffle By Investing.com - Investing.com Australia
Geron Corp reveals CEO is leaving - The Pharma Letter
H.C. Wainwright holds neutral on Geron stock post-EU approval - Investing.com
H.C. Wainwright holds neutral on Geron stock post-EU approval By Investing.com - Investing.com South Africa
Geron’s SWOT analysis: biotech stock faces pivotal year for growth - Investing.com
Geron Co. (NASDAQ:GERN) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Longtime Bay Area biotech CEO abruptly steps down - The Business Journals
Geron Announces Leadership Change with New Interim CEO - TipRanks
Geron Corp appoints interim CEO amid leadership shuffle - Investing.com India
Geron’s RYTELO gains EC approval for certain blood cancers - Investing.com
Geron announces EC approval of Rytelo - TipRanks
Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS - Yahoo Finance
Geron announces leadership transition, focuses on cancer drug potential - Investing.com
Geron CEO Scarlett to leave company - TipRanks
Geron Corporation Announces Departure Of CEO -March 11, 2025 at 04:03 pm EDT - Marketscreener.com
Geron Reshapes Leadership After FDA Win: CEO Exits as RYTELO Launch Takes Center Stage - StockTitan
Geron Corp Azioni (GERN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Geron Corp Azioni (GERN) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
SCARLETT JOHN A | Chairman, President and CEO |
Feb 27 '25 |
Buy |
1.76 |
12,500 |
22,062 |
12,500 |
Ziegler James | EVP, Chief Commercial Officer |
Feb 27 '25 |
Buy |
1.60 |
100,000 |
160,000 |
100,000 |
GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Option Exercise |
1.72 |
674,348 |
1,159,879 |
674,348 |
GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Sale |
4.56 |
674,348 |
3,073,004 |
0 |
Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Option Exercise |
1.19 |
287,900 |
341,693 |
155,400 |
Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Sale |
4.63 |
287,900 |
1,334,129 |
0 |
Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Option Exercise |
1.06 |
421,875 |
447,188 |
421,875 |
Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Sale |
4.64 |
421,875 |
1,959,609 |
0 |
SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Option Exercise |
2.54 |
600,000 |
1,524,000 |
600,000 |
SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Sale |
4.00 |
600,000 |
2,400,000 |
600,000 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):